BioAlliance Pharma SA - Product Pipeline Review - 2014

Published: Apr, 2014 | Pages: 47 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

BioAlliance Pharma SA - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'BioAlliance Pharma SA - Product Pipeline Review - 2014', provides an overview of the BioAlliance Pharma SA's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of BioAlliance Pharma SA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of BioAlliance Pharma SA including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of BioAlliance Pharma SA's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the BioAlliance Pharma SA's pipeline products

Reasons to buy

- Evaluate BioAlliance Pharma SA's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of BioAlliance Pharma SA in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the BioAlliance Pharma SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of BioAlliance Pharma SA and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of BioAlliance Pharma SA
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of BioAlliance Pharma SA and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
BioAlliance Pharma SA Snapshot 5
BioAlliance Pharma SA Overview 5
Key Information 5
Key Facts 5
BioAlliance Pharma SA - Research and Development Overview 6
Key Therapeutic Areas 6
BioAlliance Pharma SA - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
BioAlliance Pharma SA - Pipeline Products Glance 11
BioAlliance Pharma SA - Late Stage Pipeline Products 11
Pre-Registration Products/Combination Treatment Modalities 11
Phase III Products/Combination Treatment Modalities 12
BioAlliance Pharma SA - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
BioAlliance Pharma SA - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
BioAlliance Pharma SA - Drug Profiles 16
acyclovir 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
doxorubicin nanoparticle 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
miconazole 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
clonidine hydrochloride ER 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
BA-015 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
fentanyl citrate SR 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
BA-011 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
BA-016 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
BA-026 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
BA-032 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
ELP-10 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
irinotecan hydrochloride 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
BioAlliance Pharma SA - Pipeline Analysis 30
BioAlliance Pharma SA - Pipeline Products by Target 30
BioAlliance Pharma SA - Pipeline Products by Route of Administration 32
BioAlliance Pharma SA - Pipeline Products by Molecule Type 33
BioAlliance Pharma SA - Pipeline Products by Mechanism of Action 34
BioAlliance Pharma SA - Recent Pipeline Updates 36
BioAlliance Pharma SA - Dormant Projects 43
BioAlliance Pharma SA - Company Statement 44
BioAlliance Pharma SA - Locations And Subsidiaries 45
Head Office 45
Other Locations & Subsidiaries 45
Appendix 46
Methodology 46
Coverage 46
Secondary Research 46
Primary Research 46
Expert Panel Validation 46
Contact Us 47
Disclaimer 47

List of Tables
BioAlliance Pharma SA, Key Information 5
BioAlliance Pharma SA, Key Facts 5
BioAlliance Pharma SA - Pipeline by Indication, 2014 8
BioAlliance Pharma SA - Pipeline by Stage of Development, 2014 9
BioAlliance Pharma SA - Monotherapy Products in Pipeline, 2014 10
BioAlliance Pharma SA - Pre-Registration, 2014 11
BioAlliance Pharma SA - Phase III, 2014 12
BioAlliance Pharma SA - Phase II, 2014 13
BioAlliance Pharma SA - Phase I, 2014 14
BioAlliance Pharma SA - Preclinical, 2014 15
BioAlliance Pharma SA - Pipeline by Target, 2014 31
BioAlliance Pharma SA - Pipeline by Route of Administration, 2014 32
BioAlliance Pharma SA - Pipeline by Molecule Type, 2014 33
BioAlliance Pharma SA - Pipeline Products by Mechanism of Action, 2014 35
BioAlliance Pharma SA - Recent Pipeline Updates, 2014 36
BioAlliance Pharma SA - Dormant Developmental Projects,2014 43
BioAlliance Pharma SA, Subsidiaries 45